Václav's PhD project leads to founding of startup DIANA Biotechnologies
A new company DIANA Biotechnologies has been founded at IOCB Prague to develop a technology known as DIANA, or DNA-linked Inhibitor Antibody Assay, which was developed in our group by Václav Navrátil and colleagues. The unique method allows for ultrasensitive quantification of enzymes and other proteins in a solution, e.g. human blood, urine, or saliva. In practice, it should help doctors diagnose certain diseases (cancer and various infectious diseases, for instance) at an earlier stage than is possible with existing methods. Moreover, the technology has a second important application: It enables screening of large numbers of chemical substances for enzyme inhibitors and the identification of suitable compounds for further development as drug candidates.